Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)

Authors :: Suayip Yalcin
A Prokharau
Lukas Makris
Edvard Zhavrid
Gorbunova
Giordano D. Beretta
Ayumu Hosokawa
Kazumasa Fujitani
M Dvorkin
D Ganea
C. Faustino
Robert Winkler
Toshihiko Doi
K. Nishikawa
J. Tabernero
Michele Ghidini
Wasat Mansoor
Maria Alsina
K. Shitara
H.-T. Arkenau
D. Ilson
Source :: Annals of Oncology. 29:v122
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: medicine.medical_specialty
business.industry
Hematology
Placebo
Gastroenterology
Metastatic gastric cancer
03 medical and health sciences
0302 clinical medicine
Oncology
Refractory
030220 oncology & carcinogenesis
Internal medicine
medicine
Overall survival
030211 gastroenterology & hepatology
In patient
business

Full Text Access

Tools